Home > Overview of Development, Manufacturing & Global Marketing from India Dr Brian W Tempest President – Pharmaceuticals New Delhi
Overview
of Development, Manufacturing & Global Marketing from India
Dr Brian W Tempest
President – Pharmaceuticals
New Delhi
February 12, 2002
Once R&D
discovers,
Can the Indian
Pharma Industry develop, manufacture
& market around the world? R&D discovers
Global
Pharmaceutical Industry
Blockbuster Patent Expirations
(adjusted for patent
extensions)
in $ Bn
Source:
IMS World Review 2000
Rank in 2005
(Rank
in 2000)
$ 282 bn
$ 362 bn
World Pharma Markets
Source:
IMS World Review 2000
US
31%
Europe
19%
Japan
11%
Others
39%
Generics
Market in 2000 ~ USD 36 bn
Emerging Markets in 2000 ~ USD 30 bn
(Latin
America, China, India, Russia)
World Generics and Emerging Markets
Indian
Pharma Market
Manufacturing
capabilities
RANBAXY
Production
capacity of Indian Pharma Industry
Rs Crores *
*1Crore = 10
Million
RANBAXY
Investment
in Indian Pharma Industry
RANBAXY
The
Indian Pharma Market
API
manufacturing
90 -
100
250
Organized
domestic
sector
80
Exporting
International
operations
6
8
Accredited
R&D facilities
Average
spend ~ 3.5%
New
drugs research
3
70% of
pharma
Market
($
3.5b)
75% of
API
Production
($
700m)
90% of
pharma
Exports
($1.4b)
65% of
total R&D
Spend
($
75m)
80% of JVs
and foreign
investment
Ranbaxy present in all categories
Improvement in health indicators
in
India over the years
RANBAXY
Exports of
Pharmaceutical Products from India
RANBAXY
Significant
Presence
in volume terms and 14th in Value terms.
RANBAXY
Comparative
Drug Prices
31.07
12.76
Naproxen 250mg
(antiarthritic)
41.16
13.58
Haloperidol 5mg
(cardioprotective)
61.15
11.29
Atenolol 100mg
(cardiovascular)
40.89
15.26
Diltiazem 60mg
(antihpertensive)
29.90
3.82
Nifedipine 10mg
(cardiovascular)
58.56
15.45
Captopril 25mg
(antihypertensive)
121.67
16.15
Ranitidine 150mg
(anti-ulcer)
36.40
6.77
Cimetidine 200mg
(anti-ulcer)
UK
INDIA
DRUG
Rupees
RANBAXY
Key elements in the success
of
Indian Pharma Industry
by US-FDA, UK-MCA, Australian-TGA and SA-MCC
Analog
research , NDDS, Chiral research and NCEs
RANBAXY
Competitive
edge of
Indian Pharmaceutical
Companies
RANBAXY
Ranbaxy
Competitive Edges
Unique
Price advantage
RANBAXY
PCT
applications from developing countries
Company Country Applications
Strategic
Architecture for Ranbaxy �� products
Gross margins
Teachnological & Marketing complexity
NCE
NDDR
60-80%
Intermediates &
Bulk
Substances
2 - 12%
Commodity
generics
12 - 20%
Conven-tional
dosage forms
20 - 30%
Value Added/ Branded
Generics
30-40%
NDDS
OTC
45- 60%
Market
Mix - Changing Profile
Developing
Emerging
Developed
Regulatory / Technology
/ Cost Structure
Russia
China
UK
USA
Australia
Nigeria
Brazil
INDIA
Egypt
Vietnam
Thailand
S. Africa
Poland
Malaysia
5
79
16
4
67
29
��99
��04
Sales Revenue %
FW
Africa
Sri
Lanka
Japan
Business
dynamics of markets
Russia
Germany
UK
USA
W. Europe
Nigeria
Brazil
INDIA
Egypt
Vietnam
Thailand
Kenya
S. Africa
Poland
C. Europe
Advanced
Emerging
Developing
China
Regulatory /marketing
complexity
Cost / Returns
Hi
Hi
Lo
Lo
Malaysia
Myanmar
Ukraine
C. America
Mexico
Cote-d-Ivory
Ireland
Canada
Cameroon
Peru
ANZ
M.East
90��s
80��s
00��s
Internationalization �� our changing
contours
+
Advanced
Developing
+
Emerging
Innovative
research, Patents, Legal Brand marketing for Rx
products
Developmental research,
Regulatory,
Manufacturing, Marketing
Backward
integration
Competencies
Proprietary
technology platforms (NDDS), VAGs, Rx products
Generics,
Branded Generics
API,
Dosage
Form
Products
Markets
International
India
Exports
Strategy
Thank You
All Rights Reserved Powered by Free Document Search and Download
Copyright © 2011